|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Tirofiban#Warnings]] |
| {{Tirofiban}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings and Precautions==
| |
| | |
| ===General Risk of Bleeding===
| |
| | |
| Bleeding is the most common complication encountered during therapy with AGGRASTAT. Most bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac [[catheterization]]. Minimize the use of traumatic or potentially traumatic procedures such arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Fatal bleeding events have been reported [see Adverse Reactions (6.2)].
| |
| | |
| Concomitant use of[[ fibrinolytics]], oral [[anticoagulants]] and [[antiplatelet]] drugs increases the risk of bleeding.
| |
| | |
| ===Thrombocytopenia===
| |
| | |
| Profound [[thrombocytopenia]] has been reported with AGGRASTAT. Monitor platelet counts beginning about 6 hours after treatment initiation and daily thereafter. If the platelet count decreases to <90,000/mm3, monitor platelet counts to exclude [[pseudothrombocytopenia]]. If [[thrombocytopenia]] is confirmed, discontinue AGGRASTAT and [[heparin]]. Previous exposure to a glycoprotein (GP) IIb/IIIa receptor antagonist may increase the risk of developing [[thrombocytopenia]] [see Adverse Reactions (6.1)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AGGRASTAT (TIROFIBAN) INJECTION, SOLUTION [MEDICURE INTERNATIONAL INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |